CKD 702
Alternative Names: CKD-702Latest Information Update: 16 Jun 2025
At a glance
- Originator Chong Kun Dang
- Developer Chong Kun Dang; National Cancer Center (Korea)
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer
- Phase I Non-small cell lung cancer
Most Recent Events
- 25 Apr 2025 CKD 702 is still in phase I trials for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV) (NCT04667975)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV, Infusion)